Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Perspect Med Educ ; 4(1): 43-6, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25609171

ABSTRACT

In 2008, a compulsory national basic teaching qualification was introduced for all university teachers in the Netherlands. At that time all eight University Medical Centres (UMCs) and the only Faculty of Veterinary Medicine had adopted or were setting up teacher development programmes. This study explores how these programmes relate to each other and to the basic teaching qualification. To gather information on teacher development programmes in the UMCs and the Veterinary Medicine Faculty an online survey was filled out by teacher development representatives from each of them. The programmes had main features in common (e.g. competency based and portfolio assessment), but differed somewhat in contents according to the local situation. Importantly, they had all been formally accepted as equivalent to the basic teaching qualification. We consider the freedom to tailor the qualifications to the medical context as well as to the local situation of the UMCs and the Veterinary Medicine Faculty one of the major success factors and the well-established collaboration between teacher development representatives of the UMCs and the Faculty of Veterinary Medicine as another. Challenges for the future include embedding the teacher development programmes in the institutional organizations and maintaining and further developing the programmes and the competencies of the qualified teachers, e.g. in a senior qualification.

2.
J Neuropathol Exp Neurol ; 64(1): 74-81, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15715087

ABSTRACT

The molecular biology underlying the development of highly malignant peripheral nerve sheath tumors (MPNSTs) remains mostly unknown. In the present study, the expression pattern of 10 selected cell cycle components is investigated in a series of 15 MPNSTs from patients with (n = 9) or without (n = 5) neurofibromatosis type 1 (NF1). Thirteen tumors did not express the cyclin-dependent kinase inhibitor, p16(INK4A), an observation that was related to homozygote gene deletions in three tumors, heterozygote deletions in five, and gross gene rearrangements in five. The absence of protein expression in the tumors with one seemingly intact allele was not caused by promoter hypermethylation of p16(INK4A) or p14(ARF). All tumor samples expressed normal sized RB1, cyclin D3, CDK2, CDK4, p21(CIP1), and p27(KlP1) proteins, and only a single tumor showed an aberrant protein band for one of these proteins, p21(CIP1). Cyclin D1 was absent in four tumors; all except one tumor showed expression of TP53 protein, and three of nine MPNSTs had expression of normal-sized MDM2. In conclusion, this study shows that the vast majority of MPNSTs had gross rearrangements of the p16(INK4A) gene, explaining the absence of the encoded protein in the same tumors. The level of expression was equally distributed between the familial (NF1) and sporadic cases, although it should be noted that the 2 cases with p16(INK4A) expression were sporadic. The data imply that the complete absence of p16(INK4A) is sufficient for activation of the cell cycle in most MPNSTs; thus, it is not necessary for tumor proliferation to further stimulate the cycle through alteration of other central components.


Subject(s)
Cell Cycle Proteins/biosynthesis , Cell Cycle , Gene Expression Regulation, Neoplastic , Nerve Sheath Neoplasms/genetics , Nerve Sheath Neoplasms/metabolism , Neurofibromatosis 1/genetics , Neurofibromatosis 1/metabolism , Adult , Aged , Blotting, Western , Cell Cycle Proteins/genetics , Cyclin-Dependent Kinase Inhibitor p16/biosynthesis , Cyclin-Dependent Kinase Inhibitor p16/genetics , Female , Humans , Male , Middle Aged , Nerve Sheath Neoplasms/pathology , Neurofibromatosis 1/pathology , Retinoblastoma Protein/biosynthesis , Retinoblastoma Protein/genetics , Tumor Suppressor Protein p53/biosynthesis , Tumor Suppressor Protein p53/genetics
3.
Anticancer Res ; 24(1): 291-5, 2004.
Article in English | MEDLINE | ID: mdl-15015610

ABSTRACT

BACKGROUND: Chemotherapy sensitivity of soft-tissue sarcomas (STS) is limited, which may be due to multidrug resistance (MDR). MDR is associated with expression of P-glycoprotein (P-gp), Multidrug Resistance-associated Protein 1 (MRP1) and Lung Resistance-related Protein (LRP). It is unknown whether in STS metastasis is more resistant than the primary counterpart. MATERIALS AND METHODS: In 35 chemonaive STS and their metastases (86% chemonaive), MDR proteins were immunohistochemically assessed. Eleven metastases presented synchronously, 24 metachronously. Expression was scored positive (>5% positive tumour cells) or negative. RESULTS: P-gp was positive in 31/34 primaries (91%), versus 22/32 metastases (69%) (p=0.005). This difference was significant for metachronous metastases (p=0.008). MRP1 was positive in 18/32 primaries (56%) and 22/33 metastases (67%). MRP1 was more expressed in synchronous metastases than primaries (p=0.047), but for the overall group this significance disappeared. LRP expression did not differ: 27/34 primaries (80%), versus 28/34 metastases (82%). CONCLUSION: P-gp, MRP1, LRP expression in the primary tumours was high. Metastatic progression did not coincide with MDR-protein up-regulation.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , Multidrug Resistance-Associated Proteins/biosynthesis , Neoplasm Proteins/biosynthesis , Sarcoma/metabolism , Soft Tissue Neoplasms/metabolism , Vault Ribonucleoprotein Particles/biosynthesis , Down-Regulation , Drug Resistance, Multiple , Humans , Lymphatic Metastasis , Sarcoma/pathology , Sarcoma/secondary , Soft Tissue Neoplasms/pathology , Soft Tissue Neoplasms/secondary , Up-Regulation
4.
Clin Cancer Res ; 9(8): 2926-32, 2003 Aug 01.
Article in English | MEDLINE | ID: mdl-12912938

ABSTRACT

PURPOSE: Postradiation sarcoma, a sarcoma developing in a previously irradiated field, is a rare tumor. Surgery appears to be the only curative treatment option. In general the prognosis is poor, and new treatments options are needed. One study reported the expression of KIT receptor tyrosine kinase in two postradiation angiosarcomas. Success of inhibition of KIT in malignant gastrointestinal stromal tumors with imatinib mesylate seems mutation-dependent, with a favorable response in the presence of exon 11 mutations. EXPERIMENTAL DESIGN: We performed a clinical, immunohistochemical, and genetic assessment of postradiation sarcomas, including angiosarcomas. Archival tumor tissue was available from 16 patients diagnosed with a postradiation sarcoma between 1978 and 2001. Data on the first and secondary tumor, treatment, and follow-up was documented. KIT expression was assessed by immunohistochemistry. For comparison, 23 spontaneous soft tissue sarcomas of similar histological types were analyzed. Exon 11 of the c-kit gene was analyzed by direct DNA sequencing. RESULTS: Fifteen patients received initial irradiation for malignant disease and 1 patient for a benign condition. The median delivered dose was 50 Gy. The median latency period between irradiation and diagnosis of postradiation sarcomas was 222 months. Histological types included: angiosarcoma, fibrosarcoma, malignant fibrous histiocytoma, osteosarcoma, rhabdomyosarcoma, and unspecified sarcoma. In concordance with the literature, patients had a poor outcome. Only 3 of 16 patients were disease-free 43, 60, and 161 months after being diagnosed of postradiation sarcoma, all 3 having favorable tumor and treatment characteristics. Fourteen of 16 tumor samples were KIT-positive (88%). In 8 cases >80% of tumor cells stained positively. Five of 23 (22%) spontaneous soft tissue sarcomas of comparable histological types, including 2 angiosarcomas, were KIT-positive. Molecular genetic analysis of exon 11 of the c-kit gene was attainable for 13 of the 16 postradiation sarcomas. No mutations were found. CONCLUSIONS: Postradiation sarcomas are aggressive malignancies, seldom amenable to curative treatment. A majority of the analyzed tumors showed extensive expression of the KIT protein, but no mutations in exon 11 of the c-kit gene were found. Still, without the availability of effective therapies, treatment with the KIT inhibitor imatinib mesylate might be considered for patients with postradiation sarcomas.


Subject(s)
Neoplasms, Radiation-Induced/diagnosis , Proto-Oncogene Proteins c-kit/metabolism , Sarcoma/diagnosis , Soft Tissue Neoplasms/diagnosis , Adolescent , Adult , Aged , Dose-Response Relationship, Radiation , Exons , Female , Hemangiosarcoma/enzymology , Humans , Immunohistochemistry , Infant , Male , Middle Aged , Mutation , Prognosis , Radiotherapy/adverse effects , Sarcoma/enzymology , Soft Tissue Neoplasms/enzymology , Time Factors
5.
Cancer ; 97(8): 1999-2005, 2003 Apr 15.
Article in English | MEDLINE | ID: mdl-12673730

ABSTRACT

BACKGROUND: Pediatric rhabdomyosarcomas (RMS) have a more advantageous prognosis after multimodality treatment compared with adult RMS, which might be related to a decreased sensitivity to chemotherapy in adults. Resistance to chemotherapy might be conveyed by the multidrug resistance (MDR)-associated proteins P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), and lung resistance-related protein (LRP). It was therefore suggested that these proteins were expressed differently in pediatric and adult patients. METHODS: The expression of P-gp, MRP1, and LRP was assessed immunohistochemically in 45 specimens of untreated RMS: 29 were obtained from children younger than 16 years old and 16 were obtained from adults. All children had an embryonal or botryoid RMS. Among the adults, there were 10 embryonal, 3 alveolar, and 3 pleomorphic RMS. Samples were scored as negative or positive according to the percentage of immunoreactive tumor cells: 0.5 (1-5%), 1 (5-25%), 2 (26-50%), 3 (51-75%), or 4 (> 75%). RESULTS: Expression of LRP was more pronounced in embryonal and pleomorphic RMS in adults compared with RMS in children. In addition, LRP expression correlated with age at diagnosis. Alveolar RMS had remarkably low LRP expression. Expression of P-gp and MRP1 did not differ significantly between children and adults. CONCLUSIONS: In this series of embryonal and pleomorphic RMS, an increased LRP expression was observed in adults, which may explain their worse response to chemotherapy reported in other studies. In alveolar RMS, a low LRP expression was observed, suggesting that other mechanisms are responsible for the resistant phenotype in most of these tumors.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Drug Resistance, Multiple , Multidrug Resistance-Associated Proteins/analysis , Neoplasm Proteins/analysis , Rhabdomyosarcoma/chemistry , Adolescent , Adult , Aged , Cell Differentiation , Child , Child, Preschool , Drug Resistance, Neoplasm , Female , Gene Expression Regulation, Leukemic , Humans , Immunoenzyme Techniques , Infant , Infant, Newborn , Male , Middle Aged , Neoplasm Recurrence, Local , Prognosis , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/pathology , Vault Ribonucleoprotein Particles
6.
Cancer Metastasis Rev ; 21(2): 167-83, 2002.
Article in English | MEDLINE | ID: mdl-12465756

ABSTRACT

Soft tissue sarcomas (STSs) are rare tumors, notorious for early hematogenous metastasizing. Metastatic disease is seldom amenable to curative treatment; therefore new treatment modalities are required. Treatment-related and tumor-related prognostic factors can be assessed to estimate the risk for subsequent metastases, as will be discussed. By this means, high-risk patients can be defined; they are the candidates for clinical trials mandatory for treatment development. The metastatic process as well as the reaction to chemotherapy depends on the biological make-up of the tumor. Current chemotherapy regimens do not improve the survival rates of patients with metastatic disease, due to resistance mechanisms of tumor cells. New drugs with direct access to the cell death machinery in tumor cells might contribute to more effective treatment of STS patients.


Subject(s)
Sarcoma/secondary , Sarcoma/therapy , Humans , Prognosis , Sarcoma/diagnosis
7.
J Neurooncol ; 58(2): 157-65, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12164688

ABSTRACT

Identification of patients with a low grade glioma with a long-term recurrence-free survival is of clinical value as radiotherapy can be postponed until recurrence. The recurring glioma may increase in malignancy compared to the original tumor, which is possibly related to radiotherapy. We studied proliferation by counting mitotic figures and by MIB-1 labeling, apoptosis by TUNEL and expression of proteins related to cell cycle regulation by immunohistochemical analysis of p53, p21, bcl-2 and bax expression in 48 low grade gliomas. Astrocytomas (A, n = 14) and oligodendrogliomas (O, n = 4) with a recurrence-free survival of more than 9 years after surgery had a signficantly lower p53 index compared to A (n = 18) and O (n = 12) with a histopathologically documented recurrence. Additionally, the recurrence-free A had a higher p21 index. No significant differences were observed in MIB-LI, TUNEL-LI, bcl-2 and bax expression. Initially low grade gliomas and their corresponding recurrences were compared (n = 30). In the gliomas without radiotherapy (n = 15), no differences in mitotic rate, TUNEL-LI, p53, p21, bcl-2 and bax expression were found between primary tumors and their recurrences. Only MIB-LI was higher in the recurrent tumors. In the gliomas with radiotherapy (n = 15) no differences were detected in these parameters between the original tumor and the recurrent tumor except for a higher number of mitoses in the recurrent tumors. We conclude that low grade gliomas with a long-term recurrence-free survival were characterized by a low p53 protein expression and, in the case of A, a higher p21 index. We found no evidence that radiotherapy is involved in changes of proliferation, apoptosis or expression of proteins related to cell cycle regulation in recurring gliomas.


Subject(s)
Apoptosis , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Glioma/pathology , Glioma/radiotherapy , Brain Neoplasms/physiopathology , Brain Neoplasms/surgery , Cell Division , Combined Modality Therapy , Glioma/physiopathology , Glioma/surgery , Humans , Neoplasm Recurrence, Local , Survival Analysis
8.
Cancer Genet Cytogenet ; 135(1): 57-62, 2002 May.
Article in English | MEDLINE | ID: mdl-12072204

ABSTRACT

Most adult testicular germ cell tumors have a characteristic chromosomal abnormality that is an isochromosome 12p [i(12p)]. Furthermore, these tumors are characterized by a chromosome number in the triploid range and gains and losses of (parts of) specific chromosomes. Cytogenetic investigation of three cases of infantile testicular germ cell tumors, all diagnosed as yolk sac tumors, revealed highly abnormal karyotypes. We found one case to be diploid; the other two cases were in the hypertriploid/hypotetraploid range. Structural abnormalities of chromosomes 1, 3, and 6 were recurrent and no i(12p) was found. Our results, together with data from the literature, suggest that infantile and adult testicular germ cell tumors have a different origin and pathogenetic pathway. Aberrations of chromosomes 1, 3, and 6 may play an important role in the pathogenesis of infantile testicular yolk sac tumors.


Subject(s)
Chromosomes, Human, Pair 12/genetics , Chromosomes, Human/genetics , Endodermal Sinus Tumor/genetics , Germinoma/classification , Testicular Neoplasms/classification , Adult , Age Factors , Aneuploidy , Child, Preschool , Chromosome Aberrations , Chromosomes, Human/ultrastructure , Chromosomes, Human, Pair 1/genetics , Chromosomes, Human, Pair 1/ultrastructure , Chromosomes, Human, Pair 12/ultrastructure , Chromosomes, Human, Pair 3/genetics , Chromosomes, Human, Pair 3/ultrastructure , Chromosomes, Human, Pair 6/genetics , Chromosomes, Human, Pair 6/ultrastructure , Endodermal Sinus Tumor/pathology , Germinoma/genetics , Germinoma/pathology , Humans , In Situ Hybridization, Fluorescence , Infant , Male , Testicular Neoplasms/genetics , Testicular Neoplasms/pathology
9.
Sarcoma ; 6(3): 105-10, 2002.
Article in English | MEDLINE | ID: mdl-18521340

ABSTRACT

PURPOSE: Leiomyosarcomas (LMS) of deep and superficial tissues were examined to identify prognostic markers explaining their different biological behaviour and to define differences between cutaneous and subcutaneous LMS. LMS and leiomyomas (LM) of the skin were compared to and consistent differences that could aid in the (sometimes difficult) diagnosis. PATIENTS: Material was obtained from 27 patients with a deep LMS, 14 with a superficial LMS, and 21 with a LM. METHODS: Proliferation markers (mitotic and Ki-67 indices), DNA ploidy, size, grade, and the amount of apoptosis were studied. Statistical analysis was performed and survival curves were constructed by the Kaplan-Meier method and compared by the log-rank test. RESULTS: Superficial LMS were smaller than deep LMS (p < 0.05), and the overall survival of patients with a superficial LMS was better than with a deep LMS (p < 0.05).Within the group of superficial LMS only entirely subcutaneous, and not cutaneous tumors metastasized.No differences were found in the other examined parameters. Proliferation and apoptotic indices were significantly higher in superficial LMS compared to superficial LM. DISCUSSION: The difference in clinical outcome between patients with a superficial and deep LMS, seems to be related to site and size.The metastatic potential of subcutaneous LMS, however, seems to be related to location alone and not to size.The amount of apoptosis and proliferation can be used as additional criteria in the differentiation between superficial LMS and LM.

SELECTION OF CITATIONS
SEARCH DETAIL
...